ERK/MAPK signalling pathway and tumorigenesis
- PMID: 32104259
- PMCID: PMC7027163
- DOI: 10.3892/etm.2020.8454
ERK/MAPK signalling pathway and tumorigenesis
Abstract
Mitogen-activated protein kinase (MAPK) cascades are key signalling pathways that regulate a wide variety of cellular processes, including proliferation, differentiation, apoptosis and stress responses. The MAPK pathway includes three main kinases, MAPK kinase kinase, MAPK kinase and MAPK, which activate and phosphorylate downstream proteins. The extracellular signal-regulated kinases ERK1 and ERK2 are evolutionarily conserved, ubiquitous serine-threonine kinases that regulate cellular signalling under both normal and pathological conditions. ERK expression is critical for development and their hyperactivation plays a major role in cancer development and progression. The Ras/Raf/MAPK (MEK)/ERK pathway is the most important signalling cascade among all MAPK signal transduction pathways, and plays a crucial role in the survival and development of tumour cells. The present review discusses recent studies on Ras and ERK pathway members. With respect to processes downstream of ERK activation, the role of ERK in tumour proliferation, invasion and metastasis is highlighted, and the role of the ERK/MAPK signalling pathway in tumour extracellular matrix degradation and tumour angiogenesis is emphasised.
Keywords: ERK; Raf; Ras; cancer; extracellular signal-regulated kinase; mitogen-activated protein kinase; pathway; tumorigenesis.
Copyright: © Guo et al.
Figures
Similar articles
-
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.Oncogene. 2007 May 14;26(22):3291-310. doi: 10.1038/sj.onc.1210422. Oncogene. 2007. PMID: 17496923 Review.
-
Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling.Biochem Pharmacol. 2002 Sep;64(5-6):755-63. doi: 10.1016/s0006-2952(02)01135-8. Biochem Pharmacol. 2002. PMID: 12213567 Review.
-
MEK1/2 inhibitors in the treatment of gynecologic malignancies.Gynecol Oncol. 2014 Apr;133(1):128-37. doi: 10.1016/j.ygyno.2014.01.008. Epub 2014 Jan 14. Gynecol Oncol. 2014. PMID: 24434059 Review.
-
Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation.Int J Mol Sci. 2019 May 23;20(10):2530. doi: 10.3390/ijms20102530. Int J Mol Sci. 2019. PMID: 31126017 Free PMC article. Review.
-
cAMP inhibits the proliferation of retinal pigmented epithelial cells through the inhibition of ERK1/2 in a PKA-independent manner.Oncogene. 2002 Sep 5;21(39):6101-12. doi: 10.1038/sj.onc.1205765. Oncogene. 2002. PMID: 12203122
Cited by
-
Exploring the Phytochemistry, Signaling Pathways, and Mechanisms of Action of Tanacetum parthenium (L.) Sch.Bip.: A Comprehensive Literature Review.Biomedicines. 2024 Oct 10;12(10):2297. doi: 10.3390/biomedicines12102297. Biomedicines. 2024. PMID: 39457613 Free PMC article. Review.
-
Efficacy of Trametinib in Alleviating Cisplatin-Induced Acute Kidney Injury: Inhibition of Inflammation, Oxidative Stress, and Tubular Cell Death in a Mouse Model.Molecules. 2024 Jun 17;29(12):2881. doi: 10.3390/molecules29122881. Molecules. 2024. PMID: 38930946 Free PMC article.
-
A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?Explor Target Antitumor Ther. 2021;2(5):448-464. doi: 10.37349/etat.2021.00056. Epub 2021 Oct 31. Explor Target Antitumor Ther. 2021. PMID: 36045702 Free PMC article. Review.
-
Personalizing Therapy Outcomes through Mitogen-Activated Protein Kinase Pathway Inhibition in Non-Small Cell Lung Cancer.Biomedicines. 2024 Jul 5;12(7):1489. doi: 10.3390/biomedicines12071489. Biomedicines. 2024. PMID: 39062063 Free PMC article. Review.
-
Synephrine and Its Derivative Compound A: Common and Specific Biological Effects.Int J Mol Sci. 2023 Dec 15;24(24):17537. doi: 10.3390/ijms242417537. Int J Mol Sci. 2023. PMID: 38139366 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous